MGB Cancer Grand Rounds 2025-2026: Archived

Description

This activity provides on-demand archived lectures from the MGH Cancer Center Grand Rounds 2025-2026 series. As one of the leading academic cancer centers in the country, our research and clinical staff need to be educated on cutting edge information on advances and perspectives on cancer research and treatment across the full spectrum of cancer specialization. This will help clinicians understand, assess and apply this information in our rapidly advancing and highly specialized organization.  Clinicians will present and discuss this information in a multi-specialty setting. Clinicians will be informed and challenged across the organization to reach beyond their own specialization and role, and support higher levels of learning and competence for themselves, teams, and functions.

The theme of the series is "Science Derived from MGB Investigators " and kicks off Thursday September 11, 2025 at 12:00 PM EDT.  The series will cover a comprehensive array of disease areas and topics, attendees will be provided with a robust selection of sessions to bring them up to speed on the most cutting-edge research and therapies in oncology.

 


Course Director: Colin D. Weekes, MD, PhD

Coordinator: Alexandria R Bregoli ([email protected])

For questions regarding the registration process, please contact Mass General Brigham Office of Continuing Professional Development at [email protected].

You may print individual certificates throughout the year; your cumulative list of sessions attended is accessible on your transcript.

Target Audience

This activity is intended for Physicians, Nurses, APPs, trainees with specialties of Oncology,

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. To understand advances in the sequencing of treatment modalities in multidisciplinary cancer care
  2. To detail benefits and challenges of new technologies, drugs, and/or biologic agents  in cancer care
  3. To promulgate innovative patient sample collection strategies to enable impactful correlative science

Additional Information

Provided by: 

Mass General Brigham

Course summary
Course opens: 
09/01/2025
Course expires: 
06/30/2027
Cost:
$0.00

Sessions will be held weekly on Thursday from September 1, 2025 to June 30, 2026 from 12:00 to 1:00 PM.

DateSubjectSpeaker

September 11, 2025 

Severe Immunotherapy Complications: Integrating Clinical Insight with Translational InnovationTBD
September 18, 2025The Viral Like Behavior of Cancer 
September 25, 2025A New Era for AML? The Wane of Induction and the Rise of HMA Combinations 
October 9, 2025The Chabner Pioneer in Oncology Lectureship 
October 16, 2025Large language models in oncology: Turning promise into practice 
October 23, 2025ASCO Review 
October 30, 2025Identifying Metabolic Dependencies in Pancreatic Cancer  
November 6, 2025TBD 
November 13, 2025TBD 
November 20, 2025

Defining and overcoming anti-PD-1 resistance

 
December 4, 2025TBD 
December 11, 2025TBD 
Massachusetts General Brigham
Boston, MA 02114
United States

Course Directors

Colin D. Weekes, MD, PhD - Course Director
Director, Medical Oncology Research for Pancreatic Cancer,
Director, Cancer Center Grand Rounds Program
Massachusetts General Hospital

Kellyanne Jeffries, CNP
Senior Director of Oncology Advanced Practice Providers
Massachusetts General Hospital

E. Antonio Chiocca, MD, PhD
Vice President
American Association of Neurological Surgery

Gerard Doherty, MD
Surgeon-in-Chief,
Brigham and Women's Hospital &
Mass General Brigham Cancer Crowley Family Endowed Chair,
Department of Surgery,
Brigham and Women's Hospital;
Moseley Professor of Surgery,
Harvard Medical School.

Paul Nguyen, MD, MBA
Professor
Harvard Medical School;
Executive Vice-Chair of Radiation Oncology
Brigham and Women's Hospital;
Director of Genitourinary Radiation Oncology,
Dana-Farber Cancer Institute

 


DISCLOSURE SUMMARY OF RELEVANT FINANCIAL RELATIONSHIPS

MITIGATION STRATEGIES
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public. All reviewers have no relevant relationships with ineligible companies.

The following planners have reported no relevant financial relationship with an ineligible company:
Kellyanne Jeffries, CNP
E. Antonio Chiocca, MD, PhD
Gerard Doherty, MD
Paul Nguyen, MD, MBA

The following planners have reported relevant financial relationships with an ineligible company:

Colin Weekes, MD, PhD
Consultant: BMS, Novartis, Ipsen
Researcher: Novartis, Ipsen, Elicit, Dicephera

ACCREDITATION

In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AMA PRA Category 1 CreditTM
Mass General Brigham designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing
Mass General Brigham designates this activity for 1 ANCC contact hour. Nurses should only claim credit commensurate with the extent of their participation in the activity.

 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.